Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib

Lung cancer is one of the deadliest malignant tumors with limited treatment options. Although targeted therapy, using tyrosine-kinase inhibitors such as erlotinib (Erlo), has shown therapeutic benefit, only 15 % patients with mutated epidermal growth factor receptor (EGFR) in lung cancer cells are s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaofei, Chen, Keqiang, Yu, Ying, Xiang, Yi, Kim, Jae Hong, Gong, Wanghua, Huang, Jiaqiang, Shi, Guochao, Li, Qingyun, Zhou, Min, Sayers, Thomas, Tewary, Poonam, Gao, Beili, Wang, Ji Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752504/
https://www.ncbi.nlm.nih.gov/pubmed/29312591
http://dx.doi.org/10.18632/oncotarget.22596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752504/
https://www.ncbi.nlm.nih.gov/pubmed/29312591
http://dx.doi.org/10.18632/oncotarget.22596

Ejemplares similares